ArticleFrontiers in pharmacology2026

Sex-specific adverse event profiles of PDE4 inhibitors: a comparative big-data pharmacovigilance study of apremilast, crisaborole, and roflumilast in FAERS (2004-2025).

Baiqing Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.